Name | Type | Posted | Actions |
|---|---|---|---|
Notice of Intent to Sole Source_Banner.docx | DOCX | Jun 4, 2026 |
Rapidly autopsied postmortem human brain and blood specimens from sporadic Alzheimer’s disease (AD), Autosomal Dominant AD, and Controls
The National Institutes of Health (NIH) intends to award a sole-source contract to Banner Health for specialized postmortem human brain and blood specimens. This requirement, solicitation PCA-NIA-05858, supports research into Alzheimer’s disease (AD) by providing biological materials from sporadic AD, Autosomal Dominant AD, and control subjects. Technical standards include a postmortem interval of three hours or less and uniform fixation protocols for both formalin-fixed paraffin-embedded (FFPE) and frozen specimens. While the NIH has identified a primary source, capability statements submitted by June 14, 2026, will be evaluated to determine if a competitive procurement is possible. The NIH requires specimens with a postmortem interval of three hours or less to preserve biological markers for neurological research. The National Institute on Aging (NIA) requires postmortem human brain and blood specimens to support research into the molecular aspects of Alzheimer’s disease (AD). The requirement includes biological materials from sporadic AD, Autosomal Dominant AD, and control subjects.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.
Contact and place of performance
Luz Casey
Baltimore, MD 21224
USA
Rapidly autopsied postmortem human brain and blood specimens from sporadic Alzheimer’s disease (AD), Autosomal Dominant AD, and Controls. Please see attached document.